Recent Updates
Recently added Catalysts
ANNX Positive Sentiment

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

Wednesday, August 12, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Annexon, Inc. has expanded its Phase 3 program for vonaprument in geographic atrophy by adding a Month 24 dual primary endpoint, complementing the existing Month 15 primary endpoint. This expansion aims to strengthen the study's design and efficacy evaluation. Additionally, an open-label extension study has been launched to gather further long-term data on the treatment's effects.

Market Sentiment Analysis

POSITIVE FACTORS

  • Expansion of Phase 3 program indicates confidence in vonaprument.
  • Addition of Month 24 dual primary endpoint enhances study robustness.
  • Launch of open-label extension study may provide valuable long-term data.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+28%
120-day peak, hindsight
Typical move
3.8%
average across 9 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
ANX005
Phase 3 · Guillain-Barre Syndrome

Full Press Release Details

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a

Frequently Asked Questions

What is the new addition to Annexon's Phase 3 program?

Annexon has added a Month 24 dual primary endpoint to its Phase 3 program for vonaprument.

What is the purpose of the open-label extension study?

The open-label extension study aims to collect long-term data on the effects of vonaprument.

How does the new dual endpoint enhance the study?

The Month 24 dual primary endpoint complements the Month 15 endpoint, strengthening the study's design.

What condition is vonaprument targeting?

Vonaprument is being developed for geographic atrophy, a neuroinflammatory disease.

ShareAdd on Google
Tags: ANNX Viatris Investor Conferences Healthcare Annexon vonaprument geographic atrophy Phase 3 clinical trial
Last updated: Aug 12, 2026

Biotech snapshot

Cash runway
$225M liquidity · $16M/mo burn
~11 mo
Medium dilution risk
Lead asset
ANX005Phase 3
Guillain-Barre Syndrome →

Catalyst track record

+28%
best trade around ANNX's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for ANNX.

See every catalyst's timing & PoA →